NASDAQ:RTTR - Ritter Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.01
▼ -0.04 (-3.81%)
Get New Ritter Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RTTR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RTTR

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Ritter Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.01.

This chart shows the closing price for RTTR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Ritter Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/20/2018Maxim GroupReiterated RatingHoldLow
10/15/2018HC WainwrightSet Price TargetBuy$15.00High
8/15/2018HC WainwrightReiterated RatingBuy$15.00Low
6/28/2018HC WainwrightReiterated RatingBuy$15.00High
6/6/2018HC WainwrightSet Price TargetBuy$15.00Medium
5/29/2018HC WainwrightReiterated RatingBuy$15.00High
10/23/2017Roth CapitalSet Price TargetBuy$20.00N/A
10/23/2017HC WainwrightLower Price TargetBuy ➝ Buy$70.00 ➝ $15.00N/A
8/8/2017Chardan CapitalLower Price TargetBuy ➝ Buy$35.00 ➝ $15.00Medium
8/4/2017Maxim GroupReiterated RatingHoldLow
7/5/2017Maxim GroupReiterated RatingHoldLow
5/9/2017Maxim GroupReiterated RatingHoldHigh
4/12/2017Maxim GroupReiterated RatingHoldMedium
3/30/2017Chardan CapitalLower Price TargetBuy ➝ Buy$45.00 ➝ $35.00High
3/29/2017Maxim GroupDowngradeBuy ➝ HoldHigh
3/20/2017Maxim GroupReiterated RatingBuy$50.00Medium
3/14/2017Maxim GroupSet Price TargetBuy$50.00High
3/7/2017AegisReiterated RatingBuyMedium
2/27/2017Maxim GroupSet Price TargetBuy$50.00N/A
2/19/2017Chardan CapitalSet Price TargetBuy$50.00N/A
2/13/2017Maxim GroupBoost Price TargetBuy$40.00 ➝ $50.00N/A
(Data available from 1/19/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/19/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Ritter Pharmaceuticals logo
Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.
Read More

Today's Range

Now: $1.01
Low: $1.00
High: $1.03

50 Day Range

MA: $2.99
Low: $0.45
High: $4.09

52 Week Range

Now: $1.01
Low: $0.15
High: $1.27

Volume

569,425 shs

Average Volume

14,227,727 shs

Market Capitalization

$46.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Ritter Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Ritter Pharmaceuticals in the last year:
View the latest analyst ratings for RTTR.

What is the current price target for Ritter Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Ritter Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Ritter Pharmaceuticals in the next year.
View the latest price targets for RTTR.

What is the current consensus analyst rating for Ritter Pharmaceuticals?

Ritter Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for RTTR.

What other companies compete with Ritter Pharmaceuticals?

How do I contact Ritter Pharmaceuticals' investor relations team?

Ritter Pharmaceuticals' physical mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company's listed phone number is 310-203-1000 and its investor relations email address is [email protected] The official website for Ritter Pharmaceuticals is www.ritterpharmaceuticals.com.